Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06511141 · ClinicalTrials.gov registry record · NA

Sacral Neuromodulation for Male Overactive Bladder (MOAB)

A NA study of Prostate Cancer and Overactive Bladder, sponsored by Axonics.

Recruiting
Registry status
NA
Development phase
150
Enrollment target
19
Study locations

NCT06511141 is a NA study of Prostate Cancer and Overactive Bladder that is actively recruiting participants, run by Axonics. The registered enrollment target is 150 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (75% lower). The trial reports 19 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06511141, a NA study of Prostate Cancer and Overactive Bladder, is actively recruiting participants, sponsored by Axonics.

RECRUITING
Registry status
NA
Development phase
150 participants
Enrollment target
19
Study locations

Study Summary

To assess the post-market clinical outcomes of the Axonics SNM System for treatment of overactive bladder in male patients.

Interventions

  • DEVICE Axonics SNM System

Study Locations (19)

Alabama

  • University of Alabama at Birmingham - Birmingham
  • Urology Associates - Fairhope

California

  • El Camino Health - Mountain View
  • Tri Valley Urology - Murrieta

Florida

  • University of Miami - Miami
  • Advanced Urology Institute - Oxford

Louisiana

  • Louisiana State University - New Orleans
  • WK Clinical Research - Shreveport

Texas

  • Urology Partners of North Texas (UPNT) - Arlington
  • Texas Oncology - Houston

Arizona

  • Mayo Clinic - Scottsdale

Maryland

  • Anne Arundel Urology - Annapolis

Minnesota

  • Mayo Clinic - Rochester

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2024-10-22
Est. Completion 2028-03
Phase NA

Sponsor

Axonics

7 total trials

What the Registry Record Tells You About NCT06511141

The ClinicalTrials.gov registry entry for NCT06511141 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (75% lower). The listed sponsor is Axonics, which has 7 total studies on file at ClinicalTrials.gov.

The record links to 6 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which Axonics SNM System is the first listed.

NCT06511141 reports 19 study locations spanning 14 distinct geographic areas - top geographies include Alabama, California, Florida.

Frequently Asked Questions

What is clinical trial NCT06511141 about?

NCT06511141 is a clinical study titled "Sacral Neuromodulation for Male Overactive Bladder (MOAB)". To assess the post-market clinical outcomes of the Axonics SNM System for treatment of overactive bladder in male patients.

What is the current status of trial NCT06511141?

This trial is currently recruiting. It is a NA study. The enrollment target is 150 participants. The study started on 2024-10-22. Estimated completion is 2028-03.

What conditions does trial NCT06511141 study?

This clinical trial studies the following conditions: Prostate Cancer, Overactive Bladder, Benign Prostatic Hyperplasia, Prostatectomy, Urinary Frequency.

What interventions are being tested in trial NCT06511141?

The interventions under investigation include: Axonics SNM System (DEVICE).

Who is sponsoring clinical trial NCT06511141?

This trial is sponsored by Axonics, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06511141 being conducted?

This trial has 19 study locations across Alabama, Arizona, California, Florida, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.